FR2727016B1 - Compositions pharmaceutiques a base d'ondansetron - Google Patents

Compositions pharmaceutiques a base d'ondansetron

Info

Publication number
FR2727016B1
FR2727016B1 FR9513723A FR9513723A FR2727016B1 FR 2727016 B1 FR2727016 B1 FR 2727016B1 FR 9513723 A FR9513723 A FR 9513723A FR 9513723 A FR9513723 A FR 9513723A FR 2727016 B1 FR2727016 B1 FR 2727016B1
Authority
FR
France
Prior art keywords
ondansetron
pharmaceutical compositions
based pharmaceutical
pharmaceutically acceptable
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9513723A
Other languages
English (en)
French (fr)
Other versions
FR2727016A1 (fr
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Inc
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2727016(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of FR2727016A1 publication Critical patent/FR2727016A1/fr
Application granted granted Critical
Publication of FR2727016B1 publication Critical patent/FR2727016B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fertilizers (AREA)
FR9513723A 1994-11-22 1995-11-20 Compositions pharmaceutiques a base d'ondansetron Expired - Lifetime FR2727016B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (2)

Publication Number Publication Date
FR2727016A1 FR2727016A1 (fr) 1996-05-24
FR2727016B1 true FR2727016B1 (fr) 1998-04-03

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513723A Expired - Lifetime FR2727016B1 (fr) 1994-11-22 1995-11-20 Compositions pharmaceutiques a base d'ondansetron

Country Status (30)

Country Link
US (2) US5955488A (esLanguage)
EP (1) EP0793495B1 (esLanguage)
JP (1) JP3001264B2 (esLanguage)
KR (1) KR970706814A (esLanguage)
CN (1) CN1080118C (esLanguage)
AT (1) ATE193444T1 (esLanguage)
AU (1) AU704160B2 (esLanguage)
BE (1) BE1010250A3 (esLanguage)
BR (1) BR9509808A (esLanguage)
CY (1) CY2166B1 (esLanguage)
CZ (1) CZ285250B6 (esLanguage)
DE (1) DE69517332T2 (esLanguage)
DK (1) DK0793495T3 (esLanguage)
ES (1) ES2147309T3 (esLanguage)
FI (1) FI119355B (esLanguage)
FR (1) FR2727016B1 (esLanguage)
GB (2) GB9423511D0 (esLanguage)
GR (1) GR3033937T3 (esLanguage)
HU (1) HU226891B1 (esLanguage)
IL (1) IL116084A (esLanguage)
IT (1) IT1282352B1 (esLanguage)
MX (1) MX9703735A (esLanguage)
NO (1) NO306893B1 (esLanguage)
NZ (1) NZ296982A (esLanguage)
PL (1) PL181179B1 (esLanguage)
PT (1) PT793495E (esLanguage)
RU (1) RU2159614C2 (esLanguage)
TW (1) TW398976B (esLanguage)
WO (1) WO1996015785A1 (esLanguage)
ZA (1) ZA959821B (esLanguage)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
CA2392810A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
JP2004525083A (ja) * 2000-10-30 2004-08-19 テバ ファーマシューティカル インダストリーズ リミティド 塩酸オンダンセトロンの新規結晶及び溶媒和物形態並びにその製法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
CN1665823A (zh) * 2002-04-29 2005-09-07 特瓦药厂有限公司 制备1,2,3,9－四氢－9－甲基－3－[(2－甲基－1h－咪唑－1－基)甲基]－4h－咔唑－4－酮的方法
WO2003093260A1 (en) * 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
IL174758A (en) * 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
DE602005016402D1 (de) * 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1996552A1 (en) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast amantadine salt
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
PL1940366T3 (pl) * 2006-10-24 2009-09-30 Helsinn Healthcare Sa Miękkie, zawierające chlorowodorek palonosetronu kapsułki o zwiększonej stabilności i biodostępności
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) * 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
HUE066000T2 (hu) 2016-04-14 2024-06-28 Sensorion (+)-Azaszetron fül rendellenességek kezelésében történõ alkalmazásra

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE24964T1 (de) * 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
RU2159614C2 (ru) 2000-11-27
HUT77886A (hu) 1998-09-28
NZ296982A (en) 1998-06-26
FI972167L (fi) 1997-05-21
DE69517332T2 (de) 2000-11-30
CZ154997A3 (en) 1997-10-15
JP3001264B2 (ja) 2000-01-24
GB9523667D0 (en) 1996-01-24
NO306893B1 (no) 2000-01-10
DE69517332D1 (de) 2000-07-06
PL320295A1 (en) 1997-09-15
ATE193444T1 (de) 2000-06-15
EP0793495B1 (en) 2000-05-31
GB9423511D0 (en) 1995-01-11
BR9509808A (pt) 1997-10-21
FR2727016A1 (fr) 1996-05-24
MX9703735A (es) 1998-07-31
GB2295318B (en) 1998-10-28
US6063802A (en) 2000-05-16
PL181179B1 (pl) 2001-06-29
CZ285250B6 (cs) 1999-06-16
KR970706814A (ko) 1997-12-01
DK0793495T3 (da) 2000-10-09
NO972325D0 (no) 1997-05-21
BE1010250A3 (fr) 1998-04-07
CN1080118C (zh) 2002-03-06
HU226891B1 (en) 2010-01-28
NO972325L (no) 1997-05-22
EP0793495A1 (en) 1997-09-10
TW398976B (en) 2000-07-21
GB2295318A (en) 1996-05-29
AU704160B2 (en) 1999-04-15
IT1282352B1 (it) 1998-03-20
JPH10508864A (ja) 1998-09-02
WO1996015785A1 (en) 1996-05-30
CY2166B1 (en) 2002-08-23
PT793495E (pt) 2000-10-31
ZA959821B (en) 1996-07-31
IL116084A (en) 2000-01-31
GR3033937T3 (en) 2000-11-30
HK1009591A1 (en) 1999-06-04
FI119355B (fi) 2008-10-31
US5955488A (en) 1999-09-21
AU4173996A (en) 1996-06-17
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
FI972167A0 (fi) 1997-05-21
ES2147309T3 (es) 2000-09-01
ITRM950762A0 (esLanguage) 1995-11-20
IL116084A0 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
AP1637A (en) Celecoxib compositions.
MY138227A (en) Valdecoxib compositions
MY118371A (en) Tetrahydrolipstatin containing compositions
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
CA2205600A1 (en) Freeze-dried ondansetron compositions
ES2133052A1 (es) Nuevas formulaciones farmaceuticas liquidas para la via oral.

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: GLAXOSMITHKLINE INC., CA

Effective date: 20150109